• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July

    7/15/24 9:47:57 AM ET
    $ASLN
    $DATS
    $LXEO
    $MIRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Telecommunications Equipment
    Telecommunications
    Get the next $ASLN alert in real time by email

    U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 200 points on Monday.

    Following the market opening Monday, the Dow traded up 0.62% to 40,249.41 while the NASDAQ rose 0.52% to 18,493.58. The S&P 500 also rose, gaining, 0.44% to 5,639.94.

    Check This Out: Over $18M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying

    Leading and Lagging Sectors

    Information technology shares jumped by 1.1% on Monday.

    In trading on Monday, utilities shares fell by 1.3%.

    Top Headline

    The NY Empire State Manufacturing Index fell to a reading of -6.6 in July, compared to market estimates of -6.

    Equities Trading UP
                           

    • Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) shares shot up 107% to $8.39 after the company announced in-vivo preclinical study results of NanoAb.
    • Shares of DatChat, Inc. (NASDAQ:DATS) got a boost, surging 71% to $1.81.
    • MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares were also up, gaining 54% to $0.91 after the company said testing confirmed MIRA’s preliminary beliefs regarding potential treatment for neurological and neuropsychiatric disorders.

    Equities Trading DOWN

    • ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) shares dropped 42% to $1.46 after the company announced receipt of Nasdaq delisting determination.
    • Shares of Qualigen Therapeutics, Inc. (NASDAQ:QLGN) were down 21% to $0.3430 after jumping 109% on Friday.
    • Lexeo Therapeutics, Inc (NASDAQ:LXEO) was down, falling 21% to $13.82 after the company reported interim Phase 1/2 clinical data of LX2006 for the treatment of friedreich ataxia cardiomyopathy.

    Also Check This Out:This Analyst With 87% Accuracy Rate Sees More Than 12% Upside In AMD – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate Analysts

    Commodities

    In commodity news, oil traded down 0.2% to $82.07 while gold traded up 0.1% at $2,423.60.

    Silver traded down 0.4% to $31.05 on Monday, while copper fell 1% to $4.5475.

    Euro zone

    European shares were lower today. The eurozone's STOXX 600 fell 0.4%, Germany's DAX fell 0.4% and France's CAC 40 fell 0.6%. Spain's IBEX 35 Index fell 0.5%, while London's FTSE 100 fell 0.3%.

    Industrial production in the Eurozone declined 0.6% month-over-month in May following a flat reading in the prior month.

    Asia Pacific Markets

    Asian markets closed mixed on Monday, with Hong Kong's Hang Seng Index falling 1.52%, China's Shanghai Composite Index gaining 0.09% and India's S&P BSE Sensex gaining 0.18%.

    Indian merchandise trade deficit increased to $21 billion in June from $20.1 billion in the year-ago period, while wholesale prices rose by 3.36% year-over-year in June following a 2.61% increase in the prior month. Total passenger vehicle sales in India surged 5.0% year-over-year to 294,133 in June.

    Chinese retail sales increased by 2% year-over-year in June, while industrial production climbed by 5.3% year-over-year in June. The Chinese economy expanded by 0.7% in the second quarter, compared to a revised 1.5% increase in the prior quarter.

    Economics

    The NY Empire State Manufacturing Index fell to a reading of -6.6 in July, compared to market estimates of -6.

    Now Read This:

    • Top 5 Financials Stocks That May Collapse This Month
    Get the next $ASLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASLN
    $DATS
    $LXEO
    $MIRA

    CompanyDatePrice TargetRatingAnalyst
    Lexeo Therapeutics Inc.
    $LXEO
    12/18/2025$25.00Strong Buy
    Raymond James
    Lexeo Therapeutics Inc.
    $LXEO
    11/20/2025$19.00Overweight
    Cantor Fitzgerald
    Lexeo Therapeutics Inc.
    $LXEO
    10/15/2025$30.00Buy
    Guggenheim
    Lexeo Therapeutics Inc.
    $LXEO
    7/31/2025$20.00Outperform
    Oppenheimer
    Lexeo Therapeutics Inc.
    $LXEO
    6/13/2024$28.00Outperform
    Robert W. Baird
    Lexeo Therapeutics Inc.
    $LXEO
    6/6/2024$22.00Buy
    H.C. Wainwright
    Lexeo Therapeutics Inc.
    $LXEO
    11/28/2023$20.00Overweight
    JP Morgan
    Lexeo Therapeutics Inc.
    $LXEO
    11/28/2023$20.00Buy
    Stifel
    More analyst ratings

    $ASLN
    $DATS
    $LXEO
    $MIRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Otero Jose Manuel sold $19,294 worth of shares (3,016 units at $6.40), decreasing direct ownership by 2% to 125,460 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    2/20/26 5:05:09 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Townsend Richard Nolan sold $64,924 worth of shares (10,173 units at $6.38), decreasing direct ownership by 3% to 392,483 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    2/20/26 5:05:07 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Chief Operating Officer Otero Jose Manuel sold $6,684 worth of shares (721 units at $9.27), decreasing direct ownership by 1% to 63,476 units (SEC Form 4)

    4/A - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    2/20/26 5:05:04 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASLN
    $DATS
    $LXEO
    $MIRA
    SEC Filings

    View All

    SEC Form 144 filed by Lexeo Therapeutics Inc.

    144 - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    2/18/26 3:28:10 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.

    SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    2/17/26 4:38:17 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.

    SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    2/17/26 4:02:14 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASLN
    $DATS
    $LXEO
    $MIRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Myman Darin M bought $4,392 worth of shares (2,000 units at $2.20), increasing direct ownership by 1% to 184,516 units (SEC Form 4)

    4 - Myseum, Inc. (0001648960) (Issuer)

    8/28/25 6:07:47 PM ET
    $DATS
    Telecommunications Equipment
    Telecommunications

    Chief Executive Officer Myman Darin M bought $12,303 worth of shares (6,116 units at $2.01), increasing direct ownership by 3% to 182,516 units (SEC Form 4)

    4 - Myseum, Inc. (0001648960) (Issuer)

    8/19/25 4:30:40 PM ET
    $DATS
    Telecommunications Equipment
    Telecommunications

    Director Cholmondeley Paula H bought $104,852 worth of shares (15,000 units at $6.99), increasing direct ownership by 96% to 30,627 units (SEC Form 4)

    4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

    11/26/24 5:00:06 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASLN
    $DATS
    $LXEO
    $MIRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm

    JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology (I&I) therapeutics and operating a growing CDMO business, today announced that it has acquired 100% of the shares of Recipharm Israel Ltd., which operates Recipharm's site in Yavne, Israel, and entered into a long-term strategic commercial collaboration with Recipharm. The transactions significantly expand Scinai's manufacturing footprint, capabilities, and commercial positioning, strengthening its

    2/17/26 7:00:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February

    NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in February: Guggenheim Emerging Outlook: Biotech Summit 2026. Fireside chat on Thursday, February 12, 2026 at 12:30 p.m. ET in New York, NY. Oppenheimer 36th Annual Healthcare Life Sciences Conference. Fireside chat on Thursday, February 26, 2026 at 10:40 a.m. ET (virtual). The events will be webcast live under the News & Events tab in the Investors section of the Company's website. A replay of th

    2/5/26 7:30:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

    NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a series of key senior leadership appointments that underscore the company's continued and growing expertise in cardiovascular medicine and late-stage clinical development. The company also provided an update on the strategic partnership announced in June 2025 with Perceptive Xontogeny Venture Funds and venBio Partners to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform. Narinder Bhalla, MD has been appointed Chief Medical Officer, effective

    1/27/26 7:30:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASLN
    $DATS
    $LXEO
    $MIRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Lexeo Therapeutics with a new price target

    Raymond James initiated coverage of Lexeo Therapeutics with a rating of Strong Buy and set a new price target of $25.00

    12/18/25 9:11:03 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Lexeo Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Lexeo Therapeutics with a rating of Overweight and set a new price target of $19.00

    11/20/25 8:07:20 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Lexeo Therapeutics with a new price target

    Guggenheim initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $30.00

    10/15/25 8:29:39 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASLN
    $DATS
    $LXEO
    $MIRA
    Financials

    Live finance-specific insights

    View All

    Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

    JERUSALEM, Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the six months ended June 30, 2025. Six-Month 2025 Financial Summary  Revenues for the six months ended June 30, 2025, totaled $773 thousand, compared to $284 thousand for the six months ended June 30, 2024. The increase reflects the continued growth of the Company's CDMO business, which gener

    9/2/25 7:30:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

    JERUSALEM, May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the first three months ended March 31, 2025. Three (3) Months of 2025 Financial Summary Revenues for the three months ended March 31, 2025, totaled $586 thousand. The Company's CDMO unit began generating revenues in the second quarter ended June 30, 2024. As disclosed in the Company's Annual

    5/30/25 7:00:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

    JERUSALEM, Nov. 22, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its financial results for the nine months ended September 30, 2024 and provided a business update. Business Update & Recent Highlights Conversion of EIB Loan into Equity bringing shareholders' equity to $10 million On August 21, 2024, the Company announced that it had closed a Loan Restructuring Agreement, which included an amendment and restatement to the amended Finance Contract wi

    11/22/24 7:15:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASLN
    $DATS
    $LXEO
    $MIRA
    Leadership Updates

    Live Leadership Updates

    View All

    Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

    NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a series of key senior leadership appointments that underscore the company's continued and growing expertise in cardiovascular medicine and late-stage clinical development. The company also provided an update on the strategic partnership announced in June 2025 with Perceptive Xontogeny Venture Funds and venBio Partners to develop therapies for genetic cardiac diseases utilizing a novel non-viral RNA platform. Narinder Bhalla, MD has been appointed Chief Medical Officer, effective

    1/27/26 7:30:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

    Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)PC111 has already received an Orphan Drug Designation in Pemphigus by the European Medicine's AgencyAn application will be filed with the FDA for Orphan Drug and Breakthrough Designation in Pemphigus, as well as in SJS/TENScinai sees potential for accelerated approval given the severity of these diseases, PC111's innovative, non-immunosuppressive mode of action and the lack of effective alternative treatmentsJERUSALEM, March 27, 2025 /PRNewswire/ -- Scinai Imm

    3/27/25 9:25:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

    NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therapy programs. "Kyle has an exceptional track record as an operator and life sciences portfolio manager, and we are excited to welcome him to Lexeo at a time when we are advancing our pipeline and tran

    12/19/24 7:00:00 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASLN
    $DATS
    $LXEO
    $MIRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/14/24 5:49:30 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lexeo Therapeutics Inc.

    SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)

    11/14/24 4:45:58 PM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scinai Immunotherapeutics Ltd.

    SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

    11/14/24 4:28:57 PM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care